1405 / 1835
NEW DIRECTIONS IN SALVAGE: MSKCC STUDIES
1. Test Brentuximab as front-line salvage prior to ASCT
2. Test Brentuximab as “adjuvant”/maintenance post-ASCT
3. Avoid ASCT in selected patients with new check point inhibitors and ISRT